Explore more statements
Topics
Period
recent search
Showing: 1 – 05 of 10 Media Statements
–
13 October 2025
13 October 2025
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio
PARIS, FRANCE, 13 October 2025 – Ipsen announced today data to be presented at the upcoming European Society of Medical Oncology (ESMO) Symposium on 17-21 October 2025 for rare cancers and complex tumors, offering opportunities to change the course of…
–
08 October 2025
08 October 2025
Ipsen to present data across five rare liver diseases at AASLD 2025
Paris, France – October 8, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of 13 scientific abstracts at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). The abstracts span five rare…
–
06 May 2025
06 May 2025
Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC
PARIS, FRANCE, 6 May 2025 – Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced that seven abstracts with new data from its rare liver disease portfolio will be presented at the European Association for the Study of the Liver (EASL) congress,…
–
13 March 2025
13 March 2025
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
PARIS, FRANCE, March 13th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today it has been assigned long-term credit ratings of Baa3 by Moody’s and BBB- by S&P Global Ratings, both with a “Stable” outlook.
–
03 October 2024
03 October 2024
An update for healthcare professionals and patients on Increlex® (mecasermin) Injection
This important medicine, and all associated activities, will be transferred to Eton Pharmaceuticals following the signing of an asset transfer agreement. This agreement is expected to complete at the end of 2024.
Your dedicated contacts
-
Media Relations
-
